← Leaderboards
Saadyah Averick
Consegna Pharma, Inc.
$936,377
Attributed
$936,377
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $483.1K · FY2019–21$500K$375K$250K$125K$0
'19
'20
'21
Funding mix
By agency
NIH$936,377 · 3
By mechanism
R21$631,173 · 2
R41$305,204 · 1
Top collaborators
No co-investigators on record.
Most similar at Consegna Pharma, Inc.
Same institution · by research overlap
- Lawrence J Zana$2,872,488
Others in their field
Other Emerging Leaders on “Hydrophobicity”
- Arnab Kumar Chatterjee · Washington University$4,401,146
- Berthony Deslouches · University Of Pittsburgh At Pittsburgh$3,985,460
- Natura Myeku · Columbia University Health Sciences$3,828,607
- James Craig Hartman · Mdi Therapeutics, Inc.$3,203,631
- Benson Edagwa · University Of Nebraska Medical Center$3,028,839
- Xinhua Li · Nano Terra, Inc.$2,999,483
Research focus
HydrophobicityMedicalIn VivoIn VitroMu Opioid ReceptorsNaloxoneNanoparticleAntidotesLeadFormulationAdipose TissueHalf-LifeAnalogIntravenousDoseAcuteDrug Delivery SystemsDrug KineticsEnsureLaw EnforcementFda ApprovedFentanylMonitorOpioid
Grant awards (5)
Covalent Naloxone Nanoparticles for Next Generation Fentanyl Countermeasures$235,292
R21 · FY2021 · DA · contact PI
Covalent Naloxone Nanoparticles for Next Generation Fentanyl Countermeasures$210,090
R21 · FY2020 · DA · contact PI
Enhancing Osseointegration of PEEK with Straight Forward Chemical Derivation Strategy$185,791
R21 · FY2020 · AR · contact PI
Prevention of renarcotization from synthetic opioids$87,234
R41 · FY2020 · DA · contact PI
Prevention of renarcotization from synthetic opioids$217,970
R41 · FY2019 · DA · contact PI